Latest Breaking News On - சிஐசி ஒன்றுபட்டது மாநிலங்களில் - Page 2 : comparemela.com

HIV medicines among latest hard-to-find drugs available through AllianceRx Walgreens Prime

Share this article Share this article ORLANDO, Fla., May 4, 2021 /PRNewswire/  Cabenuva (cabotegravir/rilpivrine), the first and only once-monthly complete injectable treatment is available through AllianceRx Walgreens Prime for adults living with human immunodeficiency virus type 1 (HIV-1). Manufactured for ViiV Healthcare by GlaxoSmithKline, Cabenuva provides an alternative to patients who relied on a daily oral treatment regimen. HIV is a virus that attacks the body s immune system. If not treated, it can lead to acquired immunodeficiency syndrome (AIDS). 1 HIV-1 is the predominant type of HIV worldwide, making up 95 percent of all HIV cases worldwide. 2 Cabenuva a complete regimen for the treatment of HIV-1 infection in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

Assessing Pharmacodynamic Effects of Antiplatelet Agents With Different Mechanisms of Action

Chiesi USA Appoints VP of Medical Affairs to Support Continued Growth

Chiesi USA Announces Key Promotions to Business Unit Leads

Chiesi USA Announces Key Promotions to Business Unit Leads Chiesi USA Announces Key Promotions to Business Unit Leads CARY, N.C., Jan. 21, 2021 Chiesi USA (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), has announced the internal appointments of Jason Beyer as VP and Business Unit Leader of the Neonatology and Cystic Fibrosis Business Unit and Jay Meyer as VP and Business Unit Leader of the Cardiovascular Hospital Business Unit. In these roles, Mr. Beyer and Mr. Meyer will report directly to Jon Zwinski, General Manager and CEO of Chiesi USA, and serve as key contributors to the overall strategy, business growth and culture at Chiesi.

Chutes & Ladders—GSK vaccine exec Reichman splits to take biotech CEO post

(Pixabay)                  Welcome to this week s Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word or the bad from your shop to Fraiser Kansteiner, and we will feature it here at the end of each week. Another GSK vaccine exec jumps ship for biotech CEO role GlaxoSmithKline Amir Reichman is stepping down. Reichman is leaving his post as head of global vaccines engineering core technology at GSK to eventually head up operations at BiondVax Pharmaceuticals. Reichman will split duties with BiondVax’s founder and CEO Ron Babecoff until March 2 as he wraps his time at GSK. Reichman joined GSK in 2015 as part of a multibillion-dollar deal that saw GSK trade off its oncology assets for Novartis’ vaccines unit. Reichman held various positions at Novartis in its vaccine supply chain unit before becoming director of GSK’s global vaccines supply chain and then head of global vaccines engineering